Latest research on Insulin detemir

Insulin detemir is a long-acting human insulin analogue used to maintain basal levels of insulin in diabetic individuals. It is produced using recombinant DNA technology in yeast cells. This insulin analogue has a 14-C fatty acid, myristic acid, bound to the lysine amino acid at position B29. The myristoyl side chain increases self-association and albumin binding. This along with slow systemic absorption from the injection site prolongs distribution of the hormone into tissues and results in a long duration of action. Novo Nordisk markets insulin detemir under the trade name Levemir.

Insulin detemir interactions

Insulin detemir is another bioengineered insulin developed by removing a Threonine and acylating a lysine residue with 14-carbon fatty acid, both in the B chain. [source, 2016]
IV insulin Aspart with Insulin detemir was studied by Dungan et al. to determine whether an insulin algorithm could be used in a similar manner in the setting of diabetes and stress hyperglycemia following cessation of IV (IV) insulin after cardiac surgery and they found use of IV insulin Aspart to be safe in patients after cardiac surgery [26]. [source, 2015]
But the A1Chieve,9 a metacentric non-interventional study on 60000 diabetics in 28 countries, across 4 continents, over 24-weeks, evaluated the safety and effectiveness of Insulin detemir, biphasic insulin Aspart, and insulin Aspart (Novo Nordisk Inc., Plainsboro, NJ, USA), in people with type 2 diabetes mellitus, concluded that starting or switching to insulin analogues was associated with improvement in glycemic control with low frequency of hypoglycemia. [source, 2015]
This patient was earlier taking Glibenclamide, sitagliptin, and Insulin detemir (20 units). [source, 2015]
Insulin detemir differs from human insulin by the deletion of the amino acid Threonine in position 30 of the B chain, plus the addition of a C14 fatty acid chain at position 29 of the B chain. [source, 2015]
A study was recently conducted which investigated once-daily insulin degludec versus Insulin detemir, both in combination with bolus insulin Aspart in a 26 week trial, followed by another 26 week extension, in children and adolescents with T1DM. [source, 2015]
The results showed that at 26 weeks, insulin degludec in combination with insulin Aspart was noninferior to Insulin detemir in combination with insulin Aspart. [source, 2015]
Stimulations included: insulin neutral protamine Hagedorn (NPH) (Insuman Basal, Sanofi Aventis, Paris, France), insulin glargine (Lantus, Sanofi Aventis), first metabolite of glargine (M1, Sanofi Aventis), second metabolite of glargine (M2, Sanofi Aventis), glulisine (Apidra, Sanofi Aventis), lispro (Humalog, Eli Lilly, Indianapolis, IN, USA), insulin X10 (not marketed, Novo Nordisk, Bagsvaerd, Denmark), Aspart (B28Asp, Novo Nordisk), detemir (Levemir, Novo Nordisk) and insulin-like growth factor 1 (IGF1) (Increlex, Ipsen, Basking Ridge, NJ, USA). [source, 2015]
In a 26-week randomized, open-label study of patients with poorly controlled T2DM, addition of liraglutide to Metformin treatment followed by intensification with basal insulin (Insulin detemir [IDet]) showed that 61% of participants completing the run-in achieved glycated hemoglobin (HbA1C) levels of <7% (mean change −1.3%) compared with liraglutide alone [15]. [source, 2015]
There were seven inconsistencies where the mixed treatment comparison and pair-wise meta-analysis results differed substantially; namely, Exenatide 2mg/week vs insulin glargine, Exenatide 2mg/week vs Metformin, Exenatide 20μg vs Metformin, liraglutide 1.2mg vs Pioglitazone, liraglutide 1.8mg vs Pioglitazone, Pioglitazone vs Insulin detemir and Pioglitazone vs Metformin. [source, 2015]